Press release
-
Business Wire2 weeks ago
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with…
Read More » -
Business Wire2 weeks ago
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with…
Read More » -
Business Wire2 weeks ago
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs.…
Read More » -
Business Wire2 weeks ago
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs.…
Read More » -
Business Wire2 weeks ago
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs.…
Read More » -
Business Wire2 weeks ago
PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026
Two-year and post-hoc SURPASS-ET analyses highlight the impact of treatment timing, with durable responses and improved progression-free survival supporting consideration…
Read More » -
Business Wire2 weeks ago
ISG to Study UKG Pro Ecosystem Service Providers
Upcoming ISG Provider Lens® report will evaluate providers that modernize workforce operations with AI, data integration and continuous optimization STAMFORD,…
Read More » -
Business Wire2 weeks ago
ISG to Study UKG Pro Ecosystem Service Providers
Upcoming ISG Provider Lens® report will evaluate providers that modernize workforce operations with AI, data integration and continuous optimization STAMFORD,…
Read More » -
Business Wire2 weeks ago
ISG to Study UKG Pro Ecosystem Service Providers
Upcoming ISG Provider Lens® report will evaluate providers that modernize workforce operations with AI, data integration and continuous optimization STAMFORD,…
Read More » -
Business Wire2 weeks ago
ZFLOW AI’s Simulation-Guided Optimization Identifies a 1.54× Higher-Throughput Serving Configuration for DeepSeek V4-Pro on 8×B300
Working on PaleBlueDot AI’s NVIDIA B300 platform, ZFLOW AI used hardware-aware simulation to find an optimized SGLang serving configuration for…
Read More »